Global Sickle Cell Market- Industry Analysis & Outlook (2020-2030)
Sickle Cell (SC) is a genetic blood disorder caused by inheriting abnormal hemoglobin (Hb) genes from parents. Normally, red blood cells (RBC) have disc-like shapes which help them to travel throughout the blood vessels. But in the case of SC, red blood cells of a person’s blood take an abnormal sickle-like shape. Due to SC, red blood cells become sticky and inelastic. These RBCs block the blood circulation in different parts of body by getting blocked in the small blood vessels. Red blood cells live for about 120 days but these sickle cells live for only 10-20 days. There are various types of sickle cell disorders caused by different mutations in hemoglobin genes. Although, all types of sickle cell disorder have similar symptoms but they differ in their severity and nature of occurrence.
Currently, sickle cell is affecting approximately 20 to 25 million people worldwide and approximately 300 thousand births occur with sickle cell annually. Sickle cell has a high concentration rate in malaria endemic parts of worlds, especially, African, Middle Eastern and South Asian regions. In many African countries, 10% to 40% population carries sickle cell traits.
The U.S. is expected to be the first region to start the selling of sickle cell drugs due to developing drug therapies and later on, market penetration of sickle cell drugs would occur in Europe.
The global sickle cell market is expected to grow in future due to rising African-American population, economic growth, increasing healthcare expenditure and prevalence of sickle cell. Key trends of this market include progressing drug pipeline and rising research grants. However, there are some factors which can hinder growth of the market including regulatory changes, associated risks and slow adoption of treatments.
The report “Global Sickle Cell Market: Industry Analysis & Outlook (2017-2021)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S, and Europe along with the global market. The report profiles key players of the market including Novartis, Bristol-Myers Squibb, Shire Plc, Bluebird Bio and Global Blood Therapeutics Inc.
Currently, sickle cell is affecting approximately 20 to 25 million people worldwide and approximately 300 thousand births occur with sickle cell annually. Sickle cell has a high concentration rate in malaria endemic parts of worlds, especially, African, Middle Eastern and South Asian regions. In many African countries, 10% to 40% population carries sickle cell traits.
The U.S. is expected to be the first region to start the selling of sickle cell drugs due to developing drug therapies and later on, market penetration of sickle cell drugs would occur in Europe.
The global sickle cell market is expected to grow in future due to rising African-American population, economic growth, increasing healthcare expenditure and prevalence of sickle cell. Key trends of this market include progressing drug pipeline and rising research grants. However, there are some factors which can hinder growth of the market including regulatory changes, associated risks and slow adoption of treatments.
The report “Global Sickle Cell Market: Industry Analysis & Outlook (2017-2021)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S, and Europe along with the global market. The report profiles key players of the market including Novartis, Bristol-Myers Squibb, Shire Plc, Bluebird Bio and Global Blood Therapeutics Inc.
1. OVERVIEW
1.1 Sickle Cell
1.2 Types of Sickle Cell
1.3 Symptoms & Diagnosis
1.4 Treatment
2. GLOBAL MARKET
2.1 Global Sickle Cell Drug Market Forecast by Value
2.2 Sickle Cell Drug Market by Region
3. REGIONAL MARKET
3.1 The U.S.
3.1.1 The U.S. Sickle Cell Drug Market Forecast by Value
3.1.2 The U.S. Sickle Cell Patient Volume Forecast
3.1.3 The U.S. Sickle Cell Treated Patient Volume Forecast
3.1.4 The U.S. Sickle Cell Market Forecast by Treatment Cost
3.2 Europe
3.2.1 Europe Sickle Cell Drug Market Forecast by Value
3.2.2 Europe Sickle Cell Patient Volume Forecast
3.2.3 Europe Sickle Cell Treated Patient Volume Forecast
3.2.4 Europe Sickle Cell Market Forecast by Treatment Cost
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Rising American-African Population
4.1.2 Rising Economic Growth
4.1.3 Increasing Healthcare Expenditure
4.1.4 Increasing Prevalence of Sickle Cell
4.2 Key Trends
4.2.1 Progressing Drug Pipeline
4.2.2 Rising Research Grants
4.3 Challenges
4.3.1 Regulatory Challenges
4.3.2 Associated Risks
4.3.3 Slow Adoption of Treatment
5. COMPETITION
5.1 Global Market
5.1.1 Revenue Comparison of Key Players
5.1.2 Market Cap Comparison of Key Players (2016)
6. COMPANY PROFILES
6.1 Novartis
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Bristol-Myers Squibb
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Shire Plc.
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Bluebird Bio
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
6.5 Global Blood Therapeutics Inc.
6.5.1 Business Overview
6.5.2 Financial Overview
6.5.3 Business Strategies
1.1 Sickle Cell
1.2 Types of Sickle Cell
1.3 Symptoms & Diagnosis
1.4 Treatment
2. GLOBAL MARKET
2.1 Global Sickle Cell Drug Market Forecast by Value
2.2 Sickle Cell Drug Market by Region
3. REGIONAL MARKET
3.1 The U.S.
3.1.1 The U.S. Sickle Cell Drug Market Forecast by Value
3.1.2 The U.S. Sickle Cell Patient Volume Forecast
3.1.3 The U.S. Sickle Cell Treated Patient Volume Forecast
3.1.4 The U.S. Sickle Cell Market Forecast by Treatment Cost
3.2 Europe
3.2.1 Europe Sickle Cell Drug Market Forecast by Value
3.2.2 Europe Sickle Cell Patient Volume Forecast
3.2.3 Europe Sickle Cell Treated Patient Volume Forecast
3.2.4 Europe Sickle Cell Market Forecast by Treatment Cost
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Rising American-African Population
4.1.2 Rising Economic Growth
4.1.3 Increasing Healthcare Expenditure
4.1.4 Increasing Prevalence of Sickle Cell
4.2 Key Trends
4.2.1 Progressing Drug Pipeline
4.2.2 Rising Research Grants
4.3 Challenges
4.3.1 Regulatory Challenges
4.3.2 Associated Risks
4.3.3 Slow Adoption of Treatment
5. COMPETITION
5.1 Global Market
5.1.1 Revenue Comparison of Key Players
5.1.2 Market Cap Comparison of Key Players (2016)
6. COMPANY PROFILES
6.1 Novartis
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Bristol-Myers Squibb
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Shire Plc.
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Bluebird Bio
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
6.5 Global Blood Therapeutics Inc.
6.5.1 Business Overview
6.5.2 Financial Overview
6.5.3 Business Strategies
LIST OF CHARTS
Types of Sickle Cell
Sickle Cell Treatments
Global Sickle Cell Drug Market Forecast by Value (2020-2030)
Global Sickle Cell Drug Market by Region (2020/2025/2030
The U.S. Sickle Cell Drug Market Forecast by Value (2020-2030)
The U.S. Sickle Cell Patient Volume Forecast (2020-2030)
The U.S. Sickle Cell Treated Patient Volume Forecast (2020-2030)
The U.S. Sickle Cell Market Forecast by Treatment Cost (2020-2030)
Europe Sickle Cell Drug Market Forecast by Value (2021-2030)
Europe Sickle Cell Patient Volume Forecast (2021-2030)
Europe Sickle Cell Treated Patient Volume Forecast (2021-2030)
Europe Sickle Cell Market Forecast by Treatment Cost (2021-2030)
African-American Population (2012-2016)
Global GDP per Capita (2012-2016)
Global Healthcare Expenditure (2012-2016)
Revenue Comparison of Key Players (2016
Market Cap Comparison of Key Players (2016)
Novartis Net Sales by Segment (2016)
Novartis Net Sales by Region (2016)
Novartis Net Sales and Net Income (2012-2016)
Novartis R&D Expenditure (2014-2016
Bristol-Myers Squibb Revenue by Segment (2016)
Bristol-Myers Squibb Revenue by Region (2016)
Bristol-Myers Squibb Revenue and Net Earnings (2012-2016)
Bristol-Myers Squibb R&D Expenditure (2014-2016)
Shire’s Revenue by Product Segment (2016)
Shire Plc. Revenue and Net Income (2012-2016)
Shire Plc. R&D Expenditure (2014-2016)
Bluebird Bio Revenue and Net Loss (2012-2016)
Bluebird Bio R&D Expenditure (2014-2016)
Global Blood Therapeutics Inc. Net Loss (2013-2016)
Global Blood Therapeutics Inc. R&D Expenditure (2014-2016)
Types of Sickle Cell
Sickle Cell Treatments
Global Sickle Cell Drug Market Forecast by Value (2020-2030)
Global Sickle Cell Drug Market by Region (2020/2025/2030
The U.S. Sickle Cell Drug Market Forecast by Value (2020-2030)
The U.S. Sickle Cell Patient Volume Forecast (2020-2030)
The U.S. Sickle Cell Treated Patient Volume Forecast (2020-2030)
The U.S. Sickle Cell Market Forecast by Treatment Cost (2020-2030)
Europe Sickle Cell Drug Market Forecast by Value (2021-2030)
Europe Sickle Cell Patient Volume Forecast (2021-2030)
Europe Sickle Cell Treated Patient Volume Forecast (2021-2030)
Europe Sickle Cell Market Forecast by Treatment Cost (2021-2030)
African-American Population (2012-2016)
Global GDP per Capita (2012-2016)
Global Healthcare Expenditure (2012-2016)
Revenue Comparison of Key Players (2016
Market Cap Comparison of Key Players (2016)
Novartis Net Sales by Segment (2016)
Novartis Net Sales by Region (2016)
Novartis Net Sales and Net Income (2012-2016)
Novartis R&D Expenditure (2014-2016
Bristol-Myers Squibb Revenue by Segment (2016)
Bristol-Myers Squibb Revenue by Region (2016)
Bristol-Myers Squibb Revenue and Net Earnings (2012-2016)
Bristol-Myers Squibb R&D Expenditure (2014-2016)
Shire’s Revenue by Product Segment (2016)
Shire Plc. Revenue and Net Income (2012-2016)
Shire Plc. R&D Expenditure (2014-2016)
Bluebird Bio Revenue and Net Loss (2012-2016)
Bluebird Bio R&D Expenditure (2014-2016)
Global Blood Therapeutics Inc. Net Loss (2013-2016)
Global Blood Therapeutics Inc. R&D Expenditure (2014-2016)
LIST OF TABLES
Sickle Cell Prevalence
Drugs in Development (2016)
Bluebird Bio’s Product Pipeline
Sickle Cell Prevalence
Drugs in Development (2016)
Bluebird Bio’s Product Pipeline
